Sydney, Nov 11, 2015 - (ABN Newswire) - Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, today announced that the Australian Patent Office has granted a key patent covering the use of the company’s allogeneic “off-the-shelf” stem cell technology for the treatment of osteoarthritis and other inflammatory conditions for human and animal applications.
Australian patent number 2012313352, entitled “Stem cells and secretions for treatment of inflammatory conditions” provides commercial rights in Australia through to 20 September 2032. This patent is also being pursued for grant in other key territories including the USA, Japan and Europe.
The patent underpins the company’s Progenza stem cell technology which is a combination of mesenchymal stem cells and secretions from the cells. The secretions are the molecules (including cytokines and growth factors) that are secreted by mesenchymal stem cells (MSCs). Regeneus has developed technology and protocols for the production of secretions from adipose (fat)-derived MSCs and has shown that a combination of cells and secretions has a more powerful therapeutic effect than cells alone.
This patent is complimented by another Regeneus Australian patent granted in December 2014 that uses the company’s secretions technology to maintain viability and functionality of MSCs during the freezing and thawing process.
Regeneus’ Progenza technology is the subject of a Phase 1 study for the treatment of knee osteoarthritis in humans, which commenced in Q1 FY16 and is scheduled for final safety readout in Q4 FY16.
Regeneus has 49 patents or patent applications across 14 patent families, which provides a substantial Intellectual Property position for the company’s product pipeline.
About: Regeneus Ltd
Regeneus Ltd (ASX:RGS) is a clinical-stage regenerative medicine company developing a portfolio of cell therapies to address significant unmet medical needs in the human and animal health markets with a focus on musculoskeletal disorders, oncology and dermatology disease.
The company has two therapies targeting human conditions in various stages of development including two products in Phase I trials: Progenza is an allogeneic off-the-shelf adipose stem cell therapy to treat musculoskeletal conditions and RGSH4K is a human autologous personalized therapeutic cancer vaccine to treat a wide range of cancer types. The company has a stem cell secretions based cream targeting acne and other inflammatory skin conditions. The company has two therapies targeting animal conditions: CryoShot is a clinical-stage allogeneic off-the-shelf adipose stem cell therapy for the treatment of canine and equine musculoskeletal conditions and Kvax is an autologous personalized therapeutic cancer vaccine in clinical trials.
Help employers find you! Check out all the jobs and post your resume.
